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Abstract
Apelin binds to the G protein-coupled apelin receptor (APJ; gene name aplnr) to modulate
diverse physiological systems including cardiovascular function, and hydromineral and met-
abolic balance. Recently a second endogenous ligand for APJ, named apela, has been dis-
covered. We confirm that apela activates signal transduction pathways (ERK activation) in
cells expressing the cloned rat APJ. Previous studies suggest that exogenous apela is
diuretic, attributable wholly or in part to an action on renal APJ. Thus far the cellular distribu-
tion of apela in the kidney has not been reported. We have utilized in situ hybridization histo-
chemistry to reveal strong apela labelling in the inner medulla (IM), with lower levels
observed in the inner stripe of the outer medulla (ISOM), of rat and mouse kidneys. This
contrasts with renal aplnr expression where the converse is apparent, with intense labelling
in the ISOM (consistent with vasa recta labelling) and low-moderate hybridization in the IM,
in addition to labelling of glomeruli. Apelin is found in sparsely distributed cells amongst
more prevalent aplnr-labelled cells in extra-tubular regions of the medulla. This expression
profile is supported by RNA-Seq data that shows that apela, but not apelin or aplnr, is highly
expressed in microdissected rat kidney tubules. If endogenous tubular apela promotes
diuresis in the kidney it could conceivably do this by interacting with APJ in vasculature, or
via an unknown receptor in the tubules. The comparative distribution of apela, apelin and
aplnr in the rodent kidney lays the foundation for future work on how the renal apelinergic
system interacts.
Introduction
The G protein-coupled apelin receptor (APJ; gene name aplnr) is activated by the endogenous
ligand apelin [1,2]. The apelinergic system has been implicated in a wide range of homeostatic
processes, including cardiovascular control/cardio-embryogenesis, angiogenesis, hydromin-
eral balance, hypothalamic-pituitary-adrenal axis regulation, and metabolic homeostasis that
may involve a pathophysiological role in obesity [2].
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As a hormone in the periphery or neuromodulator in the brain, apelin appears to be co-
localized with APJ in some brain regions such as the paraventricular and supraoptic nuclei of
the hypothalamus, and in many peripheral tissues including anterior pituitary, lung, heart, kid-
ney, stomach and mammary glands, where it may act in an autocrine or paracrine fashion [2].
The tissue expression of aplnr is largely supported by the receptor autoradiographical localiza-
tion of APJ-binding sites [3–5].
Apelin exists as a number of proteoforms (i.e., [Pyr1]apelin-13, apelin-17, apelin-36) that
derive from post-translational modification of a 77 amino acid apelin pro-hormone precursor.
Upon binding APJ, apelin activates a myriad of signal transduction pathways that are often G
protein-dependent, including inhibition of adenylate cyclase, stimulation of MAP kinase
(ERK) phosphorylation, Akt phosphorylation that could contribute to neuroprotection, and
enhancing nitric oxide synthase activity [2]. APJ activation by apelin-13 may involve multiple
G proteins [6], while some actions involving APJ may be apelin-independent (e.g., G protein-
independent myocardial cell hypertrophy response to mechanical stretch) or apelin-dependent
(e.g., blunting myocardial hypertrophy) in the same tissue [7].
A second endogenous ligand for APJ has recently been discovered [8,9]. Originally anno-
tated as a long non-coding (nc) RNA (termed Ende [10]) expressed primarily in the definitive
endoderm during mouse embryogenesis, the apela (otherwise known as elabela or toddler)
gene is also translated [8,9]. It encodes a predicted 54 (58 in zebrafish) amino acid precursor
molecule that is highly conserved across vertebrates and is structurally distinct from the apelin
prohormone [8,9]. The apela precursor can be enzymatically processed into a number of bio-
logically active proteoforms such as apela-21 and apela-32 that may be secreted [8,9]. Apela-32
binds to APJ with an affinity (nanomolar) similar to apelin and may be more potent than ape-
lin in activating APJ signal transduction pathways in some APJ-expressing cells [11,12]. Apela
is essential for cell movement during gastrulation and in the development of zebrafish heart
and vasculature where loss of apela function usually results in embryonic lethality that can be
rescued by injection of apela mRNA [9]. Zebrafish apela null mutants invariably exhibit car-
diac dysplasia [8,9,13], reminiscent of the phenotype observed in the majority of embryonic
aplnr knockout mice [14]. Since cardiac abnormalities are not observed in embryonic apelin
knockout mice [14,15], it is possible that apela may be the main endogenous APJ ligand during
mouse cardiovascular development. Interestingly heart defects (or complete absence of cardio-
myocytes) are also observed when apela or apelin are over-expressed in zebrafish [9,16], indi-
cating that normal levels of either APJ ligand are obligatory for proper heart development.
Exogenously administered apela is anorexigenic [17], and promotes diuresis, presumably
by direct activation of APJ located in the kidney and/or indirectly by regulating arginine vaso-
pressin expression [11] in the hypothalamus. Apela activates the PI3K/Akt pathway and is
anti-apoptotic in human embryonic stem cells (ESCs) even though these cells did not express
aplnr [18], while apela-induced p53-mediated apoptosis in mouse ESCs points to a RNA-regu-
latory rather than a protein-coding function [19]. This depends on apela binding heteroge-
neous nuclear ribonucleoprotein L (hnRNPL), an inhibitory binding partner of p53 in these
cells. Whether apela acts as a protein in a non-APJ-dependent manner (e.g., via an unrelated
receptor) or as a regulatory RNA in vivo is not known.
Apela mRNA transcripts appear to be more prevalent during development [8,9,10]. They
are predominantly expressed in the heart of embryonic rodents [10] and zebrafish [8,9], and
are also detected in isolated cells from the adult rat heart [20], and in adult rat and mouse kid-
ney [10,11] by RT-PCR. The precise renal location of apela gene expression in the kidney has
not been reported. Evidence for renal apelin expression is less convincing—it appears to be
sparsely distributed in tissue endothelial cells and perhaps vascular epithelial cells and glomer-
uli [21]. In the rat and mouse kidney aplnr is mainly expressed in vascular elements (vasa
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recta) of the outer medulla and glomeruli [5,22,23]—lower levels have been described in the
rat collecting ducts as determined by RT-PCR of isolated tubule segments [22]. It has been
proposed that apelin-17, acting on the collecting duct APJ, counteracts the antidiuretic effect
of arginine vasopressin acting at the V2 receptor [24].
The aims of this study are to confirm apela bioactivity via APJ in vitro and to characterize
the anatomical relationship between apela and aplnr expression in the rat and mouse kidney
using in situ hybridization histochemistry (ISHH) with gene-specific oligonucleotides. In an
attempt to gain further insights into the possible functions of the renal apelinergic system we
have also utilized branched-chain ISHH to determine whether the apelin, apela and/or aplnr
genes are co-expressed in the same regions in the rat kidney. This distribution is supported by
RNA-Seq studies on isolated renal tubule segments. Our studies reveal that while apela and
aplnr expression overlap, apela is mainly expressed in the medullary collecting ducts and loops
of Henle whereas aplnr is highly expressed in non-tubular structures in the outer medulla. Ape-
lin expression is largely restricted to isolated cells mainly in the vicinity of aplnr cells in the
medulla. This distribution raises questions about how the two-ligand apelinergic system oper-
ates in regulating renal function.
Materials and methods
Animals
Adult (8–12 weeks old) male wildtype (n = 3) or null mutants (n = 2) mice from our aplnr
knockout colony [25] (mixture of C57BL/6 x 129X1/Sv strains) and adult (approx 275g) male
Wistar rats (n = 8) were used in this study (Sprague-Dawley rats were used for RNA-Seq—see
below). Animals were housed under constant temperature (21±2˚C), light (lights on from
0700 to 1900h) and humidity (45–50%) regimens with food and water ad libitum. Animal care
and maintenance were performed in accordance with the Animal Scientific Procedures Act
(1986) United Kingdom and approved by the Bristol University Animal Welfare and Ethical
Review body.
Cells
Chinese hamster ovary (CHO) cells were transfected with the rat aplnr cDNA (B78 [23]) as
previously described [26]. Stably-transfected clonal cells were obtained by limiting dilution,
and expression of aplnr was determined by Northern dot blots using two 32P-dATP-labelled
48bp oligonucleotide specific for the rat aplnr sequence (B78A and B78B [23]; see ISHH
below). The highest aplnr-expressing cell clones were expanded for use, and one line
(CHO-B78) was used for branched-chain in situ hybridization histochemistry and ERK signal
transduction assays (see below).
ERK immunohistochemistry and analysis
CHO-B78 cells were grown in 96-well plates at a concentration of approx 10,000 cells/well and
serum-starved (0.1% foetal calf serum) O/N. Dose-response curves were performed for 10min,
where [Pyr1]apelin-13 stimulation of ERK1/2 is maximal as established in pilot studies on
CHO-B78 cells. After incubation with 0.01-1000nM [Pyr1]apelin-13 (Bachem) or rat apela-32
(cyclized, pyroglutamated; Severn Biotech, U.K.), or vehicle (dH2O), the cells were immunos-
tained for dual phosphorylated(pp) ERK1/2 and total(t) ERK1/2—cell images were acquired
using the IN Cell Analyzer 1000 and analysis performed by In Cell Analyzer Workstation 3.5
software (GE Healthcare) as previously described [27,28]. The nuclear and cytoplasmic fluo-
rescence intensities in individual cells were quantified (in arbitrary units)—data was
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normalized to vehicle controls after subtraction of ‘no primary antibody’ backgrounds. In each
experiment the data (nuclear + cytoplasmic ppERK measurements) is mean ± SEM, n = 6
(approx 1200 cells imaged from 3 wells of a 96-well plate; experiments repeated twice).
In situ hybridization histochemistry (ISHH)
ISHH with radiolabelled oligonucelotides. Kidneys were frozen on powdered dry-ice
and stored desiccated at -80˚C prior to processing. Sections (12μm) were thaw-mounted onto
polylysine-coated slides and ISHH performed with two 35S-end-labelled 48bp-oligonucleotides
targeting apela, as described in detail for oligonucleotide probes (http://www.wsyacy.com/
SNGE/Protocols/ISHH/ISHH.html). The antisense probes used in this study were rAP-1 and
rAP-2 specific for rat apela (bp495-542 and bp849-896, respectively, in the 3’-untranslated
region of GenBank Accession XM_008772035 (LOC100912649)), and mAP-1 and mAP-2 spe-
cific for mouse apela (bp481-528 and bp832-879, respectively, in the 3’-untranslated region of
GenBank Accession NR_040692). ISHH with rat aplnr probes (B78A and B78B directed to
bp602-649 and bp886-933 of the rat aplnr, GenBank Accession NM_031349, respectively [23])
was used to compare the expression of aplnr with apela in rat kidney.
Corresponding sense probes used as negative controls gave little, or low, levels of uniform
background labelling.
Sections were exposed to X-ray film (Hyperfilm MP, Amersham) for 1–3 months at RT or
apposed to emulsion (Ilford K5) for up to a year at 4˚C (by which time the signal was satu-
rated). Film images were scanned and pseudocoloured in Image J by inverting LUX of ‘16 col-
ours’ in Lookup Tables. Emulsion-coated sections were developed manually with D-19
developer (Agar Scientific Ltd. U.K.) according to the manufacturer’s instructions, counter-
stained with toluidine blue and viewed on a Leica DM2000 microscope equipped with a Lecia
DFC70000T camera and Leica Application Suit X (LAS X) workstation.
Branched-chain ISHH. To compare the expression of apela, apelin and aplnr in the same
rat heart or kidney sections RNAscope (Advanced Cell Diagnostics; ACD) with the Multiple
Fluorescence Assay kit was used. In this technique, target-specific Z-shaped probes with over-
hangs create a ‘bridge’ that binds a preamplifier that can then bind multiple amplifiers. The
technique provides single RNA copy detection [29], typically ‘dots’, and permits rapid visuali-
zation (1 day) of low levels of mRNA (as is often observed for G protein-coupled receptors
(GPCRs)).
Three fluorescent colour combinations were available, Alexa 488 (green), Atto 550 (orange)
and Atto 647 (Far red), the colour for each target probe set dependant on which fluorescent
colour modules (Amp4 AltA-C) and channels (C1-3) are used. The proprietary probes were
designed by ACD for the following rat sequences: apela (GenBank Accession XM_008772035
(LOC100912649); bp147-1053; 12 Z probe pairs), apelin (NM_031612; bp2-996; 20 Z probe
pairs) and aplnr (NM_031349; bp147-1053; 20 Z probe pairs). RNAscope was performed on
16μm frozen sections that were post-fixed in 4% PFA, according to the ACD user protocols
(sheets#320513 and 320293). RNAscope detection of aplnr expression in CHO-APJ (B78) and
nontransfected CHO cells (grown at a density of ~125,000–175,000 cells/12-well plate contain-
ing a glass 13mm coverslip (type 1) for 2 days) followed the tissue section protocol with the
exception that pre-treatment was performed as in ACD sheet#320528. With cells, only the
aplnr probe(s) (and positive and negative probes in parallel) were used, with a blank probe in
the other two channels.
Positive (rat POLR2A, PPIB and ubiquitin (UBC); 3-plex probe set; ACD#407301) and neg-
ative (DapB; ACD#320871)) probes obtained from ACD were included in all experiments. Sec-
tions (and cells) were counterstained with DAPI as per ACD instructions.
Apela, apelin and aplnr in the kidney
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The fluorescence signal in heart ventricles and throughout the kidney was visualized under
a x40 objective on a Leica SPE single channel confocal laser scanning microscope attached to a
Leica DMi8 inverted epifluorescence microscope equipped with a Lecia DFC365FX mono-
chrome digital camera and LAS X workstation (University of Bristol Wolfson Bioimaging
Centre). Z stacks were taken of all images with a Z step size of 0.5 μm. Images were exported to
Image J (where Far-red labelling was sometimes converted to white) or Adobe Photoshop. No
attempt was made to quantitate the amount of ‘dot’ labelling.
Mining of transcriptome (RNA-Seq) data of microdissected rat renal
tubules and glomeruli
Previously unpublished high-throughput, ‘deep’ sequencing (RNA-Seq) data was retrieved
from a dataset on microdissected rat kidney tubules from adult male Sprague-Dawley rats
[30]. The precision of the technique and accuracy of the dissection was verified by establishing
the gene expression levels of several water and solute transporters with known distributions
across the tubule [30]. Since rat apela is not annotated in the rat reference DNA databases in
the original mapping of RNA-Seq reads we looked specifically in the mouse apela sequence to
find the corresponding rat homologue; the distribution of aplnr and apelin in the same kidney
structures was similarly extracted. Details of the methods and analysis have been outlined [30].
Statistical analysis
IN Cell Analyser 1000 experiments were performed in triplicate wells, with experiments per-
formed at least 2 times. Statistical analysis was with a one-way ANOVA and post hoc Dunnett’s
test with GraphPad Prism software (version 4.0b). p<0.05 was considered as statistically
significant.
Results
Studies on CHO cells
Studies on CHO cells stably transfected with the rat aplnr cDNA (B78) were used as a positive
control for the aplnr probe, confirming expression of APJ, and functional activity of apela-32
at APJ, in this cell line. Aplnr mRNA is highly expressed as punctate dots in CHO-B78 cells
(Fig 1A). The dots merge in areas of high aplnr expression (e.g., see Fig 1B). There is some var-
iability in cell-cell aplnr expression and occasional cells do not appear to exhibit any aplnr
expression (<5% from a count of 81 cells; see Fig 1B). No signal is detected in CHO-B78 cells
hybridized with negative control probes (Fig 1C)—similarly aplnr expression is not observed
in non-transfected CHO cells (Fig 1D).
Apela-32 and [Pyr1]apelin-13 stimulate ERK activation (p<0.01) in CHO-B78 cells in a
dose-responsive manner between 10−10–10-6M (Fig 2). The EC50’s are 6.9nM and 15.9nM for
[Pyr1]apelin-13 and apela-32, respectively.
Apela distribution in rat and mouse kidney
ISHH with radiolabelled oligonucleotides. The major site of apela expression in the rat
kidney is the inner medulla (IM) with weaker expression in the inner stripe of the outer
medulla (ISOM) (Fig 3A and 3B). Serial sections of the same kidneys hybridized with aplnr
probes show a pattern in the medulla that is inverted compared to apela expression—aplnr is
more highly expressed in the ISOM than IM. Aplnr is also expressed in glomeruli, visualized as
a patchy, ‘speckled’ pattern in the cortex.
Apela, apelin and aplnr in the kidney
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In the mouse kidney (Fig 4A and 4B) the apela pattern of labelling is similar to that
observed in the rat. In the cortex of both mouse and rat kidneys there was some light labelling
of isolated structures. There is no apparent difference in the distribution of apela between
aplnr wildtype and knockout mice (Fig 4A and 4B). Sense apela probes give uniform back-
ground labelling in the kidney (Fig 4C).
In emulsion-dipped sections of rat and mouse kidney apela labelling was pronounced in
tubules, particularly in the inner medulla collecting ducts (Fig 5A) whereas aplnr was most
prominently expressed in scattered, intertubular (interstitial) cells in the medulla (Fig 5B) and
in glomeruli in the cortex (Fig 5C). There was a stark transition, from high to low, in the num-
ber of labelled tubular structures between the IM and outer medulla (Fig 5D), and outer
medulla and cortex (Fig 5E).
Triple labelling of apela, apelin and aplnr cells using branched-chain ISHH. All three
genes are expressed in the adult rat heart (Fig 6A), used as positive tissue control for aplnr and
apela detection. Some dots are pinpoint while others are larger and appear to be a combination
of more than one dot. Aplnr is highly expressed in cardiomyocytes throughout the myocar-
dium in a pattern largely distinct from that of the more sparsely distributed apelin cells and the
even less abundant apela cells (Fig 6A and 6B). The majority of cells appear to express aplnr
alone, however in some cells aplnr and apelin appear to be colocalized. The occasional cells
express all three genes, aplnr and apela, or apelin or apela alone. Most apela-positive cells con-
tain only a few dots, in contrast to up to 20 dots observed in aplnr-positive cells. Negative con-
trol probes do not label (Fig 6C).
The relative number of apela-, apelin- and aplnr-expressing cells in the heart substantially
differs from that observed in the adult rat kidney, where there are many more cells expressing
apela, particularly in the IM and ISOM, than aplnr or apelin (Fig 6D). In agreement with our
ISHH results using radiolabelled probes, rat kidney apela expression is largely confined to
tubular elements (Fig 6D–6G), and is particularly pronounced in the IM. The vast majority of
aplnr and apelin expression in cells do not overlie apela-expressing cells (Fig 6D–6G). While
Fig 1. RNAscope with aplnr probes in CHO-B78 (rat APJ) and non-transfected CHO cell cultures. In
(A) clear, punctate aplnr labelling is present in the cytoplasm of the majority of CHO-B78 cells with cell-cell
variability in the levels of expression. Strongly (open arrow), moderately (arrows) and unlabelled (arrowheads)
aplnr cells in CHO-B78 cultures are shown in (B). (C) shows negative control probe on CHO-B78 cells, while
the lack of aplnr labelling in non-transfected CHO cells is shown in (D). Scale bar = 25μm.
https://doi.org/10.1371/journal.pone.0183094.g001
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most aplnr-positive cells also appear to express apelin, a few cells express aplnr or apelin alone.
As in the heart many cells express only single digit numbers of apela, apelin or aplnr dots.
We did not observe any apela or apelin labelling of glomeruli, while about 35% (17 out of
49 viewed from kidneys of 4 separate rats) of glomeruli express aplnr (only 1–5 dots/cell) in a
diffuse pattern in glomerular cells (Fig 6H).
Mining of transcriptome (RNA-Seq) data of microdissected rat renal tubules and glo-
meruli. Apela, apelin and aplnr show distinct patterns of expression along the tubule
(Table 1). Notably apela is expressed throughout the tubule with strongest expression in the
Loops of Henle and inner medullary collecting duct (IMCD), whereas apelin is absent from
the tubules. Low levels of aplnr are present in the distal convoluted tubule (DCT) and cortical
thick ascending loop of Henle (cTAL)—aplnr is not detected in collecting ducts. The RNA-Seq
data does not include extra-tubular elements such as vasa recta where ISHH shows aplnr to be
highly expressed. It confirms and extends the tubular expression of apela obtained by ISHH.
Fig 2. [Pyr1]apelin-13 and apela-32 activates ERK1/2 in CHO-B78 cells. Cells were treated for 10min at
37˚C with the indicated concentration of ligands. Representative thumbnail images acquired by the IN Cell
Analyzer 1000 show immunohistochemical staining for intracellular ppERK1/2 (green) after treatment of
CHO-B78 cells with vehicle (A) or 100nM [Pyr1]apelin-13 (B). The workstation can automatically demarcate
nucleus from cytoplasm according to DAPI (blue) nuclear staining. A dose-response curve (whole-cell
immunofluorescence expressed in arbitrary units) for [Pyr1]apelin-13 (blue) or apela-32 (green) is shown in
(C). There are no measurable dose-dependent changes in tERK levels (red) in cells stimulated with apela-32
—a similar result was obtained with cells stimulated with [Pyr1]apelin-13. The [Pyr1]apelin-13 and apela-32
stimulations were performed in separate cell wells (cells were used from the identical CHO-B78 passage
number) and processed for ERK immunohistochemistry in the same experiment. Data are expressed as
mean ± SEM, averaged from two separate experiments, each ligand concentration or vehicle (basal) with
triplicate wells, and at least triplicate fields within wells. **p<0.01 comparing stimulations to basal conditions.
https://doi.org/10.1371/journal.pone.0183094.g002
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Discussion
APJ was an orphan GPCR [23, 31] until its endogenous ligand apelin was isolated from stom-
ach extracts by ‘reverse pharmacology’ almost 20 years ago [32]. It has recently been proposed
that apela, a distinct protein unrelated to apelin, and highly conserved across vertebrates [8,9],
is a new endogenous ligand for APJ. We have confirmed previous studies showing that apela
Fig 3. Representative autoradiographic film images demonstrating apela (A) and aplnr (B) expression
in serial sections of a kidney from an adult male Wistar rat. Apela is highly expressed in the inner medulla
(IM) whereas aplnr labelling is primarily in the inner stripe of the outer medulla (ISOM). In contrast to the apela
labelling, the aplnr probes also label a subpopulation of glomeruli (patchy ‘dots’) in the cortex (CX). The film
images were exposed to film for 3 months, developed, scanned, exported to Image J and pseudocoloured. In
these images yellow-red designates high expression whereas blue-black represents negligible or no labelling
(see pseudocolour scale bar in (A)). The images are representative of results obtained from the kidneys of 8
rats. Scale bar = 500μm.
https://doi.org/10.1371/journal.pone.0183094.g003
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stimulates ERK activation in APJ-expressing cells in vitro [11]. Using ISHH to highlight gene
expression in an anatomical context we show that apela mRNA is not abundantly expressed in
the adult rat heart, and that there are relatively more apela-expressing cells in the inner, com-
pared to the outer, medulla of the rat and mouse kidney, whereas the converse is true for aplnr
in rats. In addition, we show apela to be mainly found in tubular elements in contrast to aplnr
(and apelin); findings that are supported by RNA-Seq data on microdissected rat tubular seg-
ments. In the renal medulla, apelin expression is aligned with aplnr expression, where some
cells appear to express both genes.
Fig 4. Autoradiographic film images of ISHH with antisense-apela probes in kidneys from adult male
aplnr wildtype (WT) (A,C) and knockout (KO)(B) mice. As in the rat kidney, apela labelling in the mouse
kidney is mainly located in the inner medulla (IM) with weaker labelling in the inner stripe of the outer medulla
(ISOM). There is also weak, scattered labelling in the cortex (arrowed). Background sense apela probe
labelling is shown in (C), where the image contrast was increased in Image J to show the outline of the tissue.
Pseudocolour scale bar is shown in (B). The sections were exposed to film for 5 weeks and images were
processed as in Fig 3. Scale bar = 500μm.
https://doi.org/10.1371/journal.pone.0183094.g004
Fig 5. Brightfield images of ISHH labelling of apela and aplnr transcripts (black grains) in adult rat and
mouse kidney. Apela is largely confined to tubular structures (outline of some arrowed in (A)) whereas aplnr
is mainly expressed in intertubular cells (arrowed in (B)) in the rat inner medulla (IM) and outer medulla,
respectively. Approx. 35% of cortical glomeruli also expressed aplnr, usually in a uniform distribution across
the structure (perimeter of glomerulus arrowed)—an aplnr-positive rat glomerulus is shown in (C)). There is a
clear demarcation in overall labelling in tubular structures in the transition from inner medulla (IM) to inner
zone of the outer medulla (ISOM) (D) and from the outer medulla (tubular structures arrowed in the outer
stripe of the outer medulla (OSOM)) to the cortex (CX) (E) in mouse kidneys. In D and E the insets are
approximately 4-fold magnifications of the wide-field images, showing apela labelling in tubules (one structure
arrowed) in the ISOM (D) and isolated cells (from boxed area) in the OSOM (E). Scale bar = 50μm in A-C, and
100μm in D and E.
https://doi.org/10.1371/journal.pone.0183094.g005
Apela, apelin and aplnr in the kidney
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Fig 6. Apela, apelin and aplnr expression in the adult rat heart ventricle and kidney by branched-chain
ISHH. The tissues were hybridized with RNAscope probes and processed in one day. Positive apela, apelin
and aplnr and negative control staining of the heart is shown in (A, B) and (C), respectively. In (A) aplnr-
expressing cells (green dots; labelled 1–6 with green arrows) are widely distributed in the heart myocardium.
The rare cells express only apela (red dots; labelled 7 with a red arrow). Some cells are labelled with both
aplnr + apelin (white dots) probes (labelled 8–10 with yellow arrows). A few cells express aplnr + apela +
apelin (labelled 11 with a white arrow) or aplnr + apela (labelled 12 with a purple arrow). (B) is an enlargement
of the dotted area outlined in (A). There was no labelling with negative control probes in all three channels in
the heart ventricles (C) where * denotes vessel. In the kidney inner medulla (D) the vast majority of cell
expressing apela (red dots; labelled 1–8 with red arrows) do not express aplnr (green dots) or apelin (yellow
dots). Some cells express both aplnr + apela transcripts (labelled 9 with a purple arrow) while aplnr + apelin
cells are more common (labelled 10–13 with yellow arrows). The rare cell exhibits apela + apelin + aplnr
labelling (14; white arrow). Removing the DAPI channel in (E) (corresponding image of (D)) highlights the
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In the present study the cardiac expression of apela is particularly low, with only sparse cells
expressing 1–3 mRNA transcripts/cell, which is in contrast to reports of a more widespread
apela expression as demonstrated by RT-PCR in endothelial cells, fibroblasts and cardiomyo-
cytes isolated from adult rat heart [20]. However this result is consistent with recent studies
showing apela-immunoreactivity predominantly in vascular endothelium in the ventricles of
human heart [33]. In zebrafish, apela is expressed primarily in the embryonic heart [10] and
appears to be the main APJ ligand in promoting cardiac development [8,9]. In vivo both apelin
and apela increase cardiac contractility in adult rodents and humans [2,20,33,34,35]. Identifi-
cation of apela protein expression in rat and mouse tissues may be facilitated by the availability
of apela-specific antibodies that are suitable for immunohistochemistry in these species. In
addition, global or apela-focused proteomic approaches concentrating on short peptides (such
as apela) may also be used to identify precise apela proteoforms. These proteins may exhibit
biased agonism/functional selectivity as has been demonstrated for the various apelin proteo-
forms in vitro [34,36]. Apela, like apelin, may also signal to ERK or other signalling molecules
via G protein-dependent and -independent pathways [35,37]. It is possible that apela RNA acts
in vivo as an APJ-independent regulatory ncRNA, although this has been shown to be func-
tionally relevant in only one system (apoptosis in mouse ESCs [19]) to date.
The expression of genes for one or both APJ-ligands with their receptor in the same cell, or
cells expressing either ligand gene in the close proximity of APJ-expressing cells, raises the pos-
sibility of autocrine and/or paracrine actions for the apelinergic system within the heart and
kidney. The demonstration of co-localization of receptor/ligand pairs in individual cells is not
without precedent, e.g., in the brain a GPCR may regulate the release of its own endogenous
ligand co-expressed in the same (or neighbouring) cell [38]. Aplnr and apelin appear to be co-
localized in endothelial cells in and around microvascular proliferations in brain tumour
distinction between apela (red) and aplnr/apelin expression (green and yellow, respectively) in the kidney. (F)
is an enlargement of the dotted area outlined in (D). In (G) the red channel diffuse background is enhanced to
clearly show the renal tubular apela (red) labelling. (H) shows aplnr expression (white dots; e.g., arrowed) in a
glomerulus (partial boundaries shown by dotted line). The images are representative of results obtained from
the hearts and kidneys of 3 and 4 rats, respectively. DAPI counterstaining is shown in blue. Scale bar = 50μm.
https://doi.org/10.1371/journal.pone.0183094.g006
Table 1. Relative mRNA abundance for apela, apelin and aplnr quantified by RNA-Seq in microdissected rat kidney tubules.
P
S1
P
S2
P
S3
SDL LD
LOM
LD
LIM
tAL mTAL cTAL DCT CNT CCD OMCD IMCD
Apelin 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Aplnr
(APJ)
0 0 0 0 0 0 0 0 0.1 0.2 0 0 0 0
Apela 0 0 0.5 15.3 17.6 34.1 15.9 0.4 0.5 1.2 1.1 3.7 5.5 17.5
Gene expression levels listed are maximum reads across the gene body [30]. The RefSeq IDs are NM_031612 (apelin) and NM_031349 (aplnr). Full data is
at https://hpcwebapps.cit.nih.gov/ESBL/Database/NephronRNAseq/ but does not include apela because it was unannotated (with no RefSeq ID) in rat.
Tubule analysis excludes interstitial (e.g., interstitial cells, blood cells) and vascular elements (e.g., endothelial cells) where there is Aplnr (APJ) expression
(e.g., in the ISOM). It appears that apela markedly outstrips apelin in terms of expression level. Apela appears to be expressed in all renal tubule segments
beyond the proximal tubule and is more highly expressed in medullary segments than in cortical segments. Abbreviations: Proximal tubule (P): S1; directly
attached to glomeruli; S2; straight part in medullary ray; S3; in outer medulla; SDL, Short descending limb of the loop of Henle; LDLOM, Long descending
limb of the loop of Henle (in outer medulla); LDLIM, Long descending limb of the loop of Henle (in inner medulla); tAL, Thin ascending limb of the loop of
Henle; mTAL, Medullary thick ascending limb of the loop of Henle; cTAL, Cortical thick ascending limb of the loop of Henle; DCT, Distal convoluted tubule;
CNT, Connecting tubule; CCD, Cortical collecting duct; OMCD, Outer medullary collecting duct; IMCD, Inner medullary collecting duct.
https://doi.org/10.1371/journal.pone.0183094.t001
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specimens [39] and we speculate that most aplnr and apelin co-expression in the kidney is
likely to be in vascular elements. Similarly, while aplnr-apelin-apela co-expression is rare in the
kidney, the co-localization of multiple receptor-ligand combinations (e.g., for the chemokine
receptor/ligand family [40]) in other tissues such as brain has been described, and is thought
to contribute to plasticity in responses to diverse physiological stimuli. Although apela has
high affinity for APJ and it may be assumed that when exogenously administered it binds to all
APJs, it may not always be active at APJ. For example, whereas aplnr (and apelin) knockdown
alters the expression of the GPCR CXCR4 in cultured human umbilical vein endothelial cells,
apela stimulation or knockdown has no effect [41]. In the kidney it would appear that many of
apela’s effects (e.g., on diuresis [11]) are mediated by APJ present in glomeruli and/or outer
medullary vascular elements. Intravenous apelin-17 also causes diuresis and effects haemody-
namic function in microdissected glomeruli in vitro [22]. The relative abundance of apela over
apelin in the kidney may suggest that renal apela (assuming that it is translated into functional
protein) is the more important APJ ligand in regulating renal function—this of course does
not take into account possible effects of circulating levels of apela and/or apelin. As measured
by enzyme immunoassay, apela has been detected in human plasma at slightly higher levels
than apelin [33]. We note that low levels of aplnr expression have been reported by others in
microdissected collecting ducts [22], an obvious site for exogenous or circulating apelin/apela’s
diuretic effects, whereas we do not observe significant tubular expression of aplnr. We propose
that renal apela in the collecting duct and other tubular elements may access extra-tubular APJ
in structures like the vasa recta to regulate the osmotic gradient and blood flow throughout
this region. There is close proximity of tubular and vascular elements in the medulla, and
cross-talk involving these structures has been implicated in the function of other peptide-
receptor systems involving vasoactive agents, including endogenous peptides such as endothe-
lin-1 [42,43] that is expressed throughout the nephron, collecting ducts and renal vasculature
with its cognate GPCRs ETA and ETB [44]. We cannot exclude the possibility that renal apela
disseminates into the blood to function as an endocrine hormone (e.g., like erythropoietin)
and/or acts locally or at extra-renal sites on another, currently unidentified receptor, as pro-
posed for its anti-apoptotic action in human ESCs [18].
Many questions remain to be explored. For example, does apela in its ncRNA or peptide
form(s) contribute to the pathological dispositions of some cardiovascular and metabolic con-
ditions? Apelin and apela have anti-apoptotic activity in a number of tissues and cells [2,19]
and both apelin and apela have been implicated in cardiac pathophysiology and cardiovascular
disease [1,2,34]. For example, vascular endothelium apela mRNA and/or apela levels are
reduced in pulmonary arterial hypertension in human patients and rat models, and apela-32
attenuates the remodelling of pulmonary vasculature and hypertrophy in right ventricular car-
diomyocytes [33]. In addition apela may participate with apelin in renal protection against
fibrosis, ischaemia and diabetic nephropathy [45]. Studies on how apela expression is regulated
(in concert with apelin and/or aplnr expression where the genes co-exist) may also be informa-
tive as to which APJ ligand may be active in target tissues. From a functional viewpoint, based
on studies in zebrafish [8,9], the majority of apela knockouts in rodents may not be viable and
so genetic manipulation of apela will likely require the use of inducible, conditional knockouts
or RNA-edited models, and/or RNA interference with apela-specific knockdown constructs,
to unravel its relative importance compared to apelin in regulating renal function.
Despite the fact that apela mRNA transcripts have been reported to be detected ‘exclusively’
in adult rat kidney [11], our study highlights the utility and sensitivity of branched-chain
ISHH to rapidly detect apela mRNA expression in isolated cells in other tissues such as the
heart. The full spectrum of apela-expressing tissues and the phenotype of the cells therein, and
the functional relevance of apela as a separate entity or in unison with apelin, awaits
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determination. These and other questions will benefit from a thorough characterization of the
sites of apela expression in a cellular context.
Author Contributions
Conceptualization: Anne-Marie O’Carroll, Stephen J. Lolait.
Data curation: Philip R. Griffiths.
Funding acquisition: Anne-Marie O’Carroll, Stephen J. Lolait.
Investigation: Sabrine Salih, Philip R. Griffiths, Aarifah Bijabhai, Mark A. Knepper.
Supervision: Anne-Marie O’Carroll, Stephen J. Lolait.
Validation: Anne-Marie O’Carroll, Sabrine Salih, Philip R. Griffiths, Aarifah Bijabhai, Mark
A. Knepper, Stephen J. Lolait.
Visualization: Anne-Marie O’Carroll, Philip R. Griffiths, Stephen J. Lolait.
Writing – original draft: Anne-Marie O’Carroll, Mark A. Knepper, Stephen J. Lolait.
Writing – review & editing: Anne-Marie O’Carroll, Sabrine Salih, Philip R. Griffiths, Aarifah
Bijabhai, Mark A. Knepper, Stephen J. Lolait.
References
1. Chapman NA, Dupre´ DJ, Rainey JK. The apelin receptor: physiology, pathology, cell signalling, and
ligand modulation of a peptide-activated class A GPCR. Biochem Cell Biol. 2014; 92: 431–440. https://
doi.org/10.1139/bcb-2014-0072 PMID: 25275559
2. O’Carroll A-M, Lolait SJ, Harris LE, Pope GR. The apelin receptor APJ: journey from an orphan to a mul-
tifaceted regulator of homeostasis. J Endocrinol. 2013; 219: 13–35.
3. Katugampola SD, Maguire JJ, Matthewson SR, Davenport AP. [(125)I]-(Pyr(1))Apelin-13 is a novel
radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasocon-
strictor role in man. Br J Pharmacol. 2001; 132: 1255–1260. https://doi.org/10.1038/sj.bjp.0703939
PMID: 11250876
4. Lolait SJ, Roper JA, Hazell GGJ, Li Y, Thomson FJ, O’Carroll A-M. Neuropeptide receptors. In: Murphy
D, Gainer H, editors. Molecular Neuroendocrinology: From Genome to Physiology (International Neuro-
endocrine Federation (INF) Masterclass Series). Wiley-Blackwell; 2016. pp. 195–218.
5. Pope GR, Roberts EM, Lolait SJ, O’Carroll A-M. Central and peripheral apelin receptor distribution in
the mouse: species differences with rat. Peptides. 2012; 33: 139–148. https://doi.org/10.1016/j.
peptides.2011.12.005 PMID: 22197493
6. Bai B, Jiang Y, Cai X, Chen J. Dynamics of apelin receptor/G protein coupling in living cells. Exp Cell
Research 2014; 328: 401–409.
7. Scimia MC, Hurtado C, Ray S, Metzler S, Wei K, Wang J, et al. APJ acts as a dual receptor in cardiac
hypertrophy. Nature. 2012; 488: 394–398. https://doi.org/10.1038/nature11263 PMID: 22810587
8. Chng SC, Ho L, Tian J, Reversade B. Elabela: a hormone essential for heart development signals via
the apelin receptor. Dev Cell. 2013; 27: 672–680. https://doi.org/10.1016/j.devcel.2013.11.002 PMID:
24316148
9. Pauli A, Norris ML, Valen E, Chew G-L, Gagnon JA, Zimmerman S, et al. Toddler: an embryonic signal
that promotes cell movement via apelin receptors. Science. 2014; 343: 1248636. https://doi.org/10.
1126/science.1248636 PMID: 24407481
10. Hassan AS, Hou J, Wei W, Hoodless PA. Expression of two novel transcripts in the mouse definitve
endoderm. Gene Expr Patterns. 2010; 10: 127–134. https://doi.org/10.1016/j.gep.2010.02.001 PMID:
20153842
11. Deng C, Chen H, Yang N, Feng Y, Hsueh AJW. Apela regulates fluid homeostasis by binding to the
APJ receptor to activate Gi signaling. J Biol Chem. 2015; 290: 18261–18268. https://doi.org/10.1074/
jbc.M115.648238 PMID: 25995451
12. Wang Z, Yu D, Wang M, Wang Q, Kouznetsova J, Yang R, et al. Elabela-apelin receptor signaling path-
way is functional in mammalian systems. Sci Rep. 2015; 5: 8170. https://doi.org/10.1038/srep08170
PMID: 25639753
Apela, apelin and aplnr in the kidney
PLOS ONE | https://doi.org/10.1371/journal.pone.0183094 August 17, 2017 13 / 15
13. Helker CSM, Schuermann A, Pollmann C, Chng SC, Kiefer F, Reversade B, et al. The hormonal peptide
elabela guides angioblasts to the midline during vasculogenesis. eLife. 2015; 4: e06726.
14. Charo DN, Ho M, Fajardo G, Kawana M, Kundu RK, Sheikh AY. Endogenous regulation of cardiovascu-
lar function by apelin-APJ. Am J Physiol Heart Cir Physiol. 2009; 297: H1904–H1913.
15. Kuba K, Zhang L, Imai Y, Arab S, Chen M, Maekawa Y, et al. Impaired heart contractility in apelin gene-
deficient mice associated with aging and pressure overload. Circ Res. 2007; 101: e32–e42. https://doi.
org/10.1161/CIRCRESAHA.107.158659 PMID: 17673668
16. Scott IC, Masri B, D’Amico LA, Jin S-W, Jungblut B, Wehman AM, et al. The G protein-coupled receptor
agtrl1b regulates early development of myocardial progenitors. Dev Cell. 2007; 12: 403–413. https://
doi.org/10.1016/j.devcel.2007.01.012 PMID: 17336906
17. Santoso P, Maejima Y, Kumamoto K, Takenoshita S, Shimomura K. Central action of elabela reduces
food intake and activates arginine vasopressin and corticotropin-releasing hormone neurons in the
hypothalamic paraventricular nucleus. Neuroreport. 2015; 26: 820–826. https://doi.org/10.1097/WNR.
0000000000000431 PMID: 26237243
18. Ho L, Tan SYX, Wee S, Wu Y, Tan SJC, Ramakrishna NB, et al. Elabela is an endogenous growth fac-
tor that sustains hESC self-renewal via the PI3K/Akt pathway. Cell Stem Cell. 2015; 17: 435–447.
https://doi.org/10.1016/j.stem.2015.08.010 PMID: 26387754
19. Li M, Gou H, Tripathi BK, Huang J, Jiang S, Dubois W, et al. An apela RNA-containing negative feed-
back loop regulates p53-mediated apoptosis in embryonic stem cells. Cell Stem Cell. 2015; 16: 669–
683. https://doi.org/10.1016/j.stem.2015.04.002 PMID: 25936916
20. Perje´s A, Kilpio¨ T, Ulvila J, Magga J, Alakoski T, Szabo´ Z, et al. Characterization of apela, a novel
endogenous ligand of apelin receptor, in the adult heart. Basic Res Cardiol. 2016; 111: 2–12. https://doi.
org/10.1007/s00395-015-0521-6 PMID: 26611206
21. Ripoll E, Pluvinet R, Torras J, Olivar R, Vidal A, Franquesa M, et al. In vivo therapeutic efficacy of intra-
renal CD40 silencing in a model of humoral acute rejection. Gene Ther. 2011; 18 945–952. https://doi.
org/10.1038/gt.2011.39 PMID: 21472009
22. Hus-Citharel A, Bouby N, Frugie´re A, Bodineau L, Gasc J-M, Llorens-Cortes C. Effect of apelin on glo-
merular hemodynamic function in the rat kidney. Kidney Int. 2008; 74: 486–494. https://doi.org/10.1038/
ki.2008.199 PMID: 18509323
23. O’Carroll A-M, Selby TL, Palkovits M, Lolait SJ. Distribution of mRNA encoding B78/apj, the rat homo-
logue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues. Bio-
chim Biophys Acta. 2000; 1492: 72–80. PMID: 11004481
24. Hus-Citharel A, Bodineau L, Frugie´re A, Joubert F, Bouby N, Llorens-Cortes C. Apelin counteracts
vasopressin-induced water reabsorption via cross talk between apelin and vasopressin receptor signal-
ing pathways in the rat collecting duct. Endocrinology. 2014; 155: 4483–4493. https://doi.org/10.1210/
en.2014-1257 PMID: 25157454
25. Roberts EM, Newson MJ, Pope GR, Landgraf R, Lolait SJ, O’Carroll A-M. Abnormal fluid homeostasis
in apelin receptor knockout mice. J Endocrinol. 2009; 202: 453–462. https://doi.org/10.1677/JOE-09-
0134 PMID: 19578099
26. O’Carroll A-M, Lolait SJ, Konig M, Mahan LC. Molecular cloning and expression of a pituitary somato-
statin receptor with preferential affinity for somatostain-28. Mol Pharmacol. 1992; 42: 939–946. PMID:
1362243
27. Caunt CJ, Finch AR, Sedgley KR, Oakley L, Luttrell LM, McArdle CA. Arrestin-mediated ERK activation
by gonadotropin-releasing hormone receptors: receptor-specific activation mechanisms and compart-
mentalization. J Biol Chem. 2006; 281: 2701–2710. https://doi.org/10.1074/jbc.M507242200 PMID:
16314413
28. Pope GR, Tilve S, McArdle CA, Lolait SJ, O’Carroll A-M. Agonist-induced internalization and desensiti-
zation of the apelin receptor. Mol Cell Endocrinol. 2016; 437: 108–119. https://doi.org/10.1016/j.mce.
2016.07.040 PMID: 27492965
29. Wang F, Flanagan J, Su N, Wang L-C, Bui S, Nielson A, et al. RNAscope: a novel in situ RNA analysis
platform for formalin-fixed, paraffin-embedded tissue. J Mol Diagn. 2012; 14:1–29.
30. Lee JW, Chou CL, Knepper MA. Deep Sequencing in Microdissected Renal Tubules Identifies Nephron
Segment-Specific Transcriptomes. J Am Soc Nephrol. 2015; 26: 2669–2677. https://doi.org/10.1681/
ASN.2014111067 PMID: 25817355
31. O’Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, et al. A human gene that shows identity
with the gene encoding the angiotensin receptor is located on chromosome 11. Gene. 1993; 136: 355–
360. PMID: 8294032
Apela, apelin and aplnr in the kidney
PLOS ONE | https://doi.org/10.1371/journal.pone.0183094 August 17, 2017 14 / 15
32. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zhou MX, et al. Isolation and characterization
of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun.
1998; 251: 471–476. https://doi.org/10.1006/bbrc.1998.9489 PMID: 9792798
33. Yang P, Read C, Kuc RE, Buonincontri G, Southwood M, Torella R, et al. Elabela/toddler is an endoge-
nous agonist of the apelin APJ receptor in the adult cardiovascular system, and endogenous adminis-
tration of the peptide compensates for the downregulation of its expression in pulmonary arterial
hypertension. Circulation. 2017.
34. Yang P, Maguire JJ, Davenport AP. Apelin, Elabela/Toddler, and biased agonists as novel therapeutic
agents in the cardiovascular system. Trends Pharmacol Sci. 2015; 36: 560–567. https://doi.org/10.
1016/j.tips.2015.06.002 PMID: 26143239
35. Murza A, Sainsily X, Coquerel D, Coˆte´ J, Marx P, Besserer-Offroy E, et al. Discovery and structure-
activity relationship of a bioactive fragment of elabela that modulates vascular and cardiac functions. J
Med Chem. 2016; 59: 2962–2972. https://doi.org/10.1021/acs.jmedchem.5b01549 PMID: 26986036
36. Masri B, Morin N, Pedebernade L, Knibiehler B, Audigier Y. The apelin receptor is coupled to Gi1 or Gi2
protein and is differentially desensitized by apelin fragments. J Biol Chem. 2006; 281: 18317–18326.
https://doi.org/10.1074/jbc.M600606200 PMID: 16679320
37. Ceraudo E, Galanth C, Carpentier E, Banegas-Font I, Schonegge A-M, Alvear-Perez R, et al. Biased
signaling favoring Gi over β-arrestin promoted by an apelin fragment lacking the C-terminal phenylala-
nine. J Biol Chem. 2014; 289: 24599–24610. https://doi.org/10.1074/jbc.M113.541698 PMID:
25012663
38. Hazell GGJ, Hindmarch CC, Pope GR, Roper JA, Lightman SL, Murphy D, et al. G protein-coupled
receptors in the hypothalamic paraventricular and supraoptic nuclei—serpentine gateways to neuroen-
docrine homeostasis. Front Neuroendocrinol. 2012; 33: 45–66. https://doi.org/10.1016/j.yfrne.2011.07.
002 PMID: 21802439
39. Ka¨lin RE, Kretz MP, Meyer AM, Kispert A, Heppner FL, Bra¨ndli AW. Paracrine and autocrine mecha-
nisms of apelin signaling govern embryonic and tumor angiogenesis. Dev Biol. 2007; 305: 599–614.
https://doi.org/10.1016/j.ydbio.2007.03.004 PMID: 17412318
40. Zeisel A, Muñoz-Manchado AB, Codeluppi S, Lo¨nnerberg P, La Manno G, Jure´us A, et al. Cell types in
the mouse cortex and hippocampus revealed by single-cell RNA-seq. Science. 2015; 347: 1138–1142.
https://doi.org/10.1126/science.aaa1934 PMID: 25700174
41. Papangeli I, Kim J, Maier I, Park S, Lee A, Kang Y, et al. MicroRNA 139-5p coordinates APLNR-
CXCR4 crosstalk during vascular maturation. Nature Commun. 2016; 7: 11268.
42. Evans RG, Eppel GA, Anderson WP, Denton KM. Mechanisms underlying the differential control of
blood flow in the renal medulla and cortex. J Hypertens. 2004; 22: 1439–1451. PMID: 15257161
43. Kennedy-Lydon TM, Crawford C, Wildman SSP, Peppiatt-Wildman. Renal pericytes: regulators of med-
ullary blood flow. Acta Physiol (Oxf). 2013; 207: 212–225.
44. Vignon-Zellweger N, Heiden S, Miyauchi T, Emoto N. Endothelin and endothelin receptors in renal and
cardiovascular systems. Life Sci. 2012; 91: 490–500. https://doi.org/10.1016/j.lfs.2012.03.026 PMID:
22480517
45. Nishida M, Hamaoka K. The apelin-APJ system: its role in renal physiology and potential therapeutic
applications for renal disease. OA Nephrol. 2013; 1: 7.
Apela, apelin and aplnr in the kidney
PLOS ONE | https://doi.org/10.1371/journal.pone.0183094 August 17, 2017 15 / 15
